Rebecca Margaret Richards, MD
Pediatric Medicine · Madison
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · University of Wisconsin Medical Foundation Inc · 2,537 clinicians in this group
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Richards’s office at (608) 263-6400 to ask if they take your plan before you enroll.
California Medical Board record
Licence A141781 · Delinquent
Licence status: Delinquent · since 2016 · expires 2023-11-30 · Oregon Health & Science University School of Medicine.
License renewal fee has not been paid. No practice is permitted.
Matched on the licence number without its letter prefix; check the name before relying on it.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
State licence records
1 licence
- Washington MDRE.ML.60369075Physician And Surgeon Residency Limited License · since 2013 · expires 2016-07-31ExpiredNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
Money from drug and device companies
$26 in 2025
A payment is not proof that care is biased.
| Chiesi USA | Kengreal | $26 | 1 payment
|
See the published payment
| Chiesi USA | Meals · 2025-03-27 | Kengreal | $26 |
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Alexion Pharmaceuticals, Inc. · A Phase 3, Open Label, Single Arm, Multicenter Study of Ravulizumab in Pediatric Patients With Persistent Complement Mediated Thrombotic Microangiopathy (Tma) After Hematopoietic Stem Cell Transplant (Hsct) · 2025 | Their institution | $41,491 |
| GlaxoSmithKline, LLC. · Phase 1/2 Dose Determination and Dose Expansion Study of Cobolimab in · 2025 | Their institution | $37,193 |
| Alexion Pharmaceuticals, Inc. · A Phase 3, Open Label, Single Arm, Multicenter Study of Ravulizumab in Pediatric Patients With Persistent Complement Mediated Thrombotic Microangiopathy (Tma) After Hematopoietic Stem Cell Transplant (Hsct) · 2024 | Their institution | $21,099 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 77.4 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1205178530
- Licence
- CA 141781, WA ML60369075, WI 77281-20California A141781: Delinquent · expires 2023-11-30Washington MDRE.ML.60369075: Expired
- Trained
- Oregon Health Sciences University School of Medicine, 2013
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2080P0207X (2080P0207X); Federal specialty code 207RH0003X (207RH0003X); Pediatrics (208000000X)
- Mailing address
- 7974 Uw Health Ct, Middleton, WI, 53562
- NPI first listed
- 2013-03-25
- NPI last updated
- 2022-09-02
- NPI record certified
- 2022-09-02
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 4800 Sand Point Way Ne, Seattle, WA, 98105 · 300 Pasteur Dr, Stanford, CA, 94305